| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion due to NICE appraisal TA135: Pemetrexed for the treatment of malignant pleural mesothelioma |
|
Medicine details |
|
| Medicine name | pemetrexed (Alimta®) |
| Formulation | powder for concentrate for solution for infusion |
| Reference number | 245 |
| Indication | In combination with cisplatin for the treatment of chemotherapy naive patients with unresectable malignant pleural mesothelioma |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 24/10/2005 |
| NICE guidance | TA135: Pemetrexed for the treatment of malignant pleural mesothelioma |